Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25442053.
- Also identified by DOI 10.1016/j.eururo.2014.11.031.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.
Medical subject headings
- Antineoplastic Agents
- BCG Vaccine
- Delivery of Health Care
- Urinary Bladder Neoplasms